Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer.
A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as the primary end point is ongoing. PROSTVAC immunotherapy contains the transgenes for prostate-specific antigen and three costimulatory molecules (designated TRICOM). Research suggests that PROSTVAC not only targets prostate-specific antigen, but also other tumor antigens via antigen cascade. PROSTVAC is well tolerated and has been safely combined with other cancer therapies, including hormonal therapy, radiotherapy, another immunotherapy and chemotherapy. Even greater benefits of PROSTVAC may be recognized in earlier-stage disease and low-disease burden settings where immunotherapy can trigger a long-lasting immune response.
Written by:
Shore ND. Are you the author?
Carolina Urologic Research Center, 823 82nd Parkway, Myrtle Beach, SC 29572, USA.
Reference: Immunotherapy. 2014 Mar;6(3):235-47.
doi: 10.2217/imt.13.176
PubMed Abstract
PMID: 24762070
UroToday.com Prostate Cancer Immunotherapy Section
